AU2006223002A1 - Macromolecules comprising a thioether cross-link - Google Patents

Macromolecules comprising a thioether cross-link Download PDF

Info

Publication number
AU2006223002A1
AU2006223002A1 AU2006223002A AU2006223002A AU2006223002A1 AU 2006223002 A1 AU2006223002 A1 AU 2006223002A1 AU 2006223002 A AU2006223002 A AU 2006223002A AU 2006223002 A AU2006223002 A AU 2006223002A AU 2006223002 A1 AU2006223002 A1 AU 2006223002A1
Authority
AU
Australia
Prior art keywords
antibody
antibodies
composition
link
thioether cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006223002A
Other languages
English (en)
Inventor
Mark Schenerman
Guillermo I. Tous
Ziping Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2006223002A1 publication Critical patent/AU2006223002A1/en
Assigned to MEDIMMUNE, LLC reassignment MEDIMMUNE, LLC Alteration of Name(s) of Applicant(s) under S113 Assignors: MEDIMMUNE, INC.
Priority to AU2012241127A priority Critical patent/AU2012241127A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2006223002A 2005-03-14 2006-03-14 Macromolecules comprising a thioether cross-link Abandoned AU2006223002A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012241127A AU2012241127A1 (en) 2005-03-14 2012-10-15 Macromolecules comprising a thioether cross-link

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66172405P 2005-03-14 2005-03-14
US60/661,724 2005-03-14
US69913805P 2005-07-13 2005-07-13
US60/699,138 2005-07-13
PCT/US2006/009311 WO2006099481A2 (en) 2005-03-14 2006-03-14 Macromolecules comprising a thioether cross-link

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012241127A Division AU2012241127A1 (en) 2005-03-14 2012-10-15 Macromolecules comprising a thioether cross-link

Publications (1)

Publication Number Publication Date
AU2006223002A1 true AU2006223002A1 (en) 2006-09-21

Family

ID=36992404

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006223002A Abandoned AU2006223002A1 (en) 2005-03-14 2006-03-14 Macromolecules comprising a thioether cross-link

Country Status (6)

Country Link
US (2) US7786273B2 (enExample)
EP (1) EP1858911A4 (enExample)
JP (1) JP2008536815A (enExample)
AU (1) AU2006223002A1 (enExample)
CA (1) CA2600844A1 (enExample)
WO (1) WO2006099481A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532027A (ja) * 2006-03-28 2009-09-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
CA2697922A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
JP2010537985A (ja) * 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
BRPI0819063A2 (pt) 2007-11-27 2020-08-18 The University Of British Columbia método para tratamento de artrite, anticorpo, hibridoma, antagonista de 14-3-3, usos de um antagonista de 14-3-3, composições farmacêuticas, método para redução da expressão de mmp no sinóvio de um paciente e usos de uma composição farmacêutica
WO2009126304A1 (en) * 2008-04-11 2009-10-15 Biogen Idec Ma Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds
KR20150084836A (ko) * 2012-11-05 2015-07-22 메디뮨 엘엘씨 벤조나아제 부재 하의 시나지스 분리 방법
BR112017008383A2 (en) * 2014-10-31 2018-07-31 Medimmune, Llc improved production method
GB201603291D0 (en) 2016-02-25 2016-04-13 Binding Site Group The Ltd Antibodies
US20190048064A1 (en) * 2016-02-25 2019-02-14 The Binding Site Group Limited Antibodies
WO2018075954A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
AU2017345786B2 (en) 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11312761B2 (en) 2016-10-21 2022-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
GB201708262D0 (en) 2017-05-23 2017-07-05 Binding Site Group Ltd Assay for plasma cell associated disease
CN108017717B (zh) * 2018-01-24 2019-08-16 首都医科大学宣武医院 一种用于体外高效定向扩增的嵌合抗原受体及其应用
CN113166236A (zh) * 2018-09-21 2021-07-23 北卡罗来纳大学查佩尔希尔分校 限制穿过黏液的合成粘合剂
GB202007047D0 (en) 2020-05-13 2020-06-24 Binding Site Group Ltd Mass spectrometry controls
US20220268783A1 (en) * 2021-02-19 2022-08-25 Waters Technologies Corporation Methods for peptide mapping of adeno-associated virus (aav) proteins
IL328264A (en) 2023-11-14 2026-07-01 Janssen Pharmaceuticals Inc Anti-Respiratory Syncytial Virus Antibodies and Their Uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003493A1 (en) * 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5091542A (en) * 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
AU664855B2 (en) * 1991-08-09 1995-12-07 Winfried Kolbeck Lanthionine bridged peptides
US6897044B1 (en) * 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
ATE328582T1 (de) * 1999-04-23 2006-06-15 Mitsubishi Chem Corp Antikörper und polyalkylenglycol gebundenes liposom
US20060123504A1 (en) * 2004-12-07 2006-06-08 Avigenics, Inc. Methods of producing polyclonal antibodies
US20060286548A1 (en) * 2005-06-16 2006-12-21 Gregory Liposky Method of making recombinant human antibodies for use in biosensor technology

Also Published As

Publication number Publication date
EP1858911A2 (en) 2007-11-28
WO2006099481A2 (en) 2006-09-21
CA2600844A1 (en) 2006-09-21
WO2006099481A3 (en) 2007-04-19
US20090030187A1 (en) 2009-01-29
US20060216284A1 (en) 2006-09-28
JP2008536815A (ja) 2008-09-11
EP1858911A4 (en) 2009-12-16
US7786273B2 (en) 2010-08-31

Similar Documents

Publication Publication Date Title
US7786273B2 (en) Macromolecules comprising a thioether cross-link
US20100278929A1 (en) Antibody formulations having optimized aggregation and fragmentation profiles
JP4934426B2 (ja) 抗体のヒト化
US20090297514A1 (en) Humanization of antibodies
EP2484696A1 (en) Antagonistic human light-specific human monoclonal antibodies
US20060228350A1 (en) Framework-shuffling of antibodies
EP3526256A1 (en) Anti-lag-3 antibodies and methods of use thereof
EP3215538A1 (en) Anti-cd39 antibodies and uses thereof
JP2013013425A (ja) 抗体のフレームワーク・シャッフル
AU2015271685A1 (en) Human monoclonal antibodies to ganglioside GD2
JP2020517242A (ja) 抗ＡｐｏＣ３抗体およびその使用方法
AU2012241127A1 (en) Macromolecules comprising a thioether cross-link
AU2012207043A1 (en) Antibody formulations having optimized aggregation and fragment profiles
CN101273061A (zh) 具有优化的聚集和片段化特性的抗体制剂
WO2024073474A2 (en) Anti-pla2g10 antibodies and methods of use
HK40006949A (en) Anti-tim-3 antibodies and methods of use thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted